Research Analysts’ updated eps estimates for Monday, August 14th:

Audentes Therapeutics (NASDAQ:BOLD) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “

BioTime (NYSEMKT:BTX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

Babcock (NYSE:BW) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Babcock & Wilcox Enterprises, Inc. offers energy technology and services primarily for the nuclear, fossil and renewable power markets as well as a premier advanced technology and mission critical defense contractor. Babcock & Wilcox Enterprises, Inc. is headquartered in Charlotte, N.C. “

Calix (NYSE:CALX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Calix is a global leader in access innovation. Its Unified Access portfolio of broadband communications access systems and software enables communications service providers worldwide to transform their networks and become the broadband provider of choice to their subscribers. “

Caseys General Stores (NASDAQ:CASY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Casey’s General Stores, Inc. operate convenience stores under the name Casey’s General Store in Midwestern states, primarily Iowa, Missouri and Illinois. The stores carry a broad selection of food (including freshly prepared foods such as pizza, donuts and sandwiches), beverages, tobacco products, health and beauty aids, automotive products and other non-food items. In addition, all stores offer gasoline for sale on a self-service basis. “

Condor Hospitality Trust (NASDAQ:CDOR) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Condor Hospitality Trust, Inc. is a self-administered real estate investment trust. The Company specializes in the investment and ownership of upper midscale and upscale, premium-branded select-service, extended stay and limited service hotels. Condor Hospitality Trust, Inc., formerly known as Supertel Hospitality, Inc., is based in Norfolk, United States. “

Cidara Therapeutics (NASDAQ:CDTX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. “

Codexis (NASDAQ:CDXS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. “

CECO Environmental Corp. (NASDAQ:CECE) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “CECO ENVIRONMENTAL CORP. manufactures and sells, primarily in the United States, of fiber bed mist eliminators to the chemical, printing, plating, power generation, food processing, waste incineration and textile industries. “

Compass Minerals International (NYSE:CMP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Compass Minerals is the largest producer of rock, or highway deicing, salt in North America and the United Kingdom and operates the largest highway deicing salt mines in these regions. The company is also the third largest producer of general trade salt in North America and the second largest in the United Kingdom, serving major retailers, agricultural cooperatives and food producers. In addition, Compass is the largest producer of sulfate of potash in North America, which is used in the production of specialty fertilizers. “

CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (NASDAQ:COTQF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Allscripts Healthcare Solutions (NASDAQ:MDRX) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. They currently have a $17.00 price target on the stock. The analysts wrote, “2Q17 recap. Non-GAAP revenue was $428 million compared to FactSet consensus of $426 million. With Netsmart now mostly annualized, non-GAAP revenue grew 7.8% y/y. Adjusted EPS was $0.15 (in line with our estimate and consensus) vs. $0.14 a year ago. Bookings were impressive and grew to $407 million.””

XOMA Corporation (NASDAQ:XOMA) had its hold rating reaffirmed by analysts at Wedbush.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.